 CAMBRIDGE, Mass.--BUSINESS WIRE--Aura Biosciences Inc. NASDAQ: AURA, a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate VDC therapies for multiple oncology indications, today announced the presentation of preclinical data for its first VDC product candidate, AU-011, which is being developed for the treatment of Non-Muscle Invasive Bladder Cancer NMIBC. The results will be presented as part of the 2022 American Society of Clinical Oncology ASCO 